ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $958,412 | +8.2% | 10,235 | +3.2% | 0.62% | +15.9% |
Q2 2023 | $885,412 | +11.5% | 9,921 | +34.0% | 0.53% | +5.5% |
Q1 2023 | $793,903 | -10.4% | 7,404 | +2.1% | 0.51% | -18.1% |
Q4 2022 | $885,926 | -7.0% | 7,254 | -21.4% | 0.62% | -9.8% |
Q3 2022 | $953,000 | -18.2% | 9,227 | -26.4% | 0.68% | -17.3% |
Q2 2022 | $1,165,000 | -29.4% | 12,529 | -10.9% | 0.83% | -20.5% |
Q1 2022 | $1,651,000 | +22.6% | 14,065 | +40.5% | 1.04% | +30.6% |
Q4 2021 | $1,347,000 | -39.0% | 10,009 | -27.8% | 0.80% | -44.3% |
Q3 2021 | $2,210,000 | +52.8% | 13,868 | +26.2% | 1.43% | +46.0% |
Q2 2021 | $1,446,000 | +8.6% | 10,991 | +6.3% | 0.98% | -0.2% |
Q1 2021 | $1,332,000 | -4.0% | 10,339 | +24.3% | 0.98% | -11.0% |
Q4 2020 | $1,387,000 | +18.9% | 8,316 | +10.0% | 1.10% | +3.0% |
Q3 2020 | $1,167,000 | +1.3% | 7,561 | -2.9% | 1.07% | -6.0% |
Q2 2020 | $1,152,000 | +22.8% | 7,789 | -6.5% | 1.14% | +1.3% |
Q1 2020 | $937,803 | -34.7% | 8,328 | -19.3% | 1.13% | -18.8% |
Q4 2019 | $1,436,000 | – | 10,323 | – | 1.39% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |